Current and future developments in the pharmacology of asthma and COPD: ERS seminar, Naples 2022

Pharmacological management of airway obstructive diseases is a fast-evolving field. Several advances in unravelling disease mechanisms as well as intracellular and molecular pathways of drug action have been accomplished. While the clinical translation and implementation of in vitro results to the bedside remains challenging, advances in comprehending the mechanisms of respiratory medication are expected to assist clinicians and scientists in identifying meaningful read-outs and designing clinical studies. This European Respiratory Society Research Seminar, held in Naples, Italy, 5–6 May 2022, focused on current and future developments of the drugs used to treat asthma and COPD; on mechanisms of drug action, steroid resistance, comorbidities and drug interactions; on prognostic and therapeutic biomarkers; on developing novel drug targets based on tissue remodelling and regeneration; and on pharmacogenomics and emerging biosimilars. Related European Medicines Agency regulations are also discussed, as well as the seminar's position on the above aspects. European pneumologists and pharmacologists review the pharmacology of drugs currently used to treat asthma and COPD and the challenges for novel drugs based on precision medicine, tissue remodelling and regeneration, pharmacogenomics and biosimilars https://bit.ly/42h55HS

• Publication year

  2023

• Venue

  Breathe

• Publication date

  2023-06-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1183/20734735.0267-2022PMID 37377851PMCID 10292790
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• IMPACT OF THE COVID-19 PANDEMIC ON HOSPITAL ADMISSION RATE, LENGTH OF STAY, AND MORTALITY RATE FOR PATIENTS WITH COPD EXACERBATION: A RETROSPECTIVE STUDY

  2022cited by this paper
• Dual bronchodilation for the treatment of COPD: From bench to bedside

  2022cited by this paper
• Astegolimab, an anti-ST2, in chronic obstructive pulmonary disease (COPD-ST2OP): a phase 2a, placebo-controlled trial.

  2022cited by this paper
• A transcriptomics-guided drug target discovery strategy identifies receptor ligands for lung regeneration

  2022cited by this paper
• Oral surveillance and JAK inhibitor safety: the theory of relativity

  2022cited by this paper
• Lessons From the Success and Failure of Targeted Drugs for Rheumatoid Arthritis: Perspectives for Effective Basic and Translational Research

  2022cited by this paper
• Recent advances in the immunopathogenesis of severe asthma.

  2022cited by this paper
• Effect of tezepelumab on airway inflammatory cells, remodelling, and hyperresponsiveness in patients with moderate-to-severe uncontrolled asthma (CASCADE): a double-blind, randomised, placebo-controlled, phase 2 trial.

  2021cited by this paper
• The sputum transcriptome better predicts COPD exacerbations after the withdrawal of inhaled corticosteroids than sputum eosinophils

  2021cited by this paper
• T helper 17 cells and corticosteroid insensitivity in severe asthma.

  2021cited by this paper
• A multi-omics approach to delineate sputum microbiome-associated asthma inflammatory phenotypes

  2021cited by this paper
• Inhaled Phosphodiesterase Inhibitors for the Treatment of Chronic Obstructive Pulmonary Disease

  2021cited by this paper
• Efficacy and Safety of Itepekimab in Patients with Moderate-to-Severe Asthma.

  2021cited by this paper
• Safety and efficacy of itepekimab in patients with moderate-to-severe COPD: a genetic association study and randomised, double-blind, phase 2a trial.

  2021cited by this paper
• New Drugs for Airway Diseases

  2021cited by this paper
• Bronchial thermoplasty in asthma: an exploratory histopathological evaluation in distinct asthma endotypes/phenotypes

  2021cited by this paper
• Repairing damaged lungs using regenerative therapy

  2021cited by this paper
• Comparison of genome-wide gene expression profiling by RNA Sequencing versus microarray in bronchial biopsies of COPD patients before and after inhaled corticosteroid treatment: does it provide new insights?

  2021cited by this paper
• Tezepelumab in Adults and Adolescents with Severe, Uncontrolled Asthma.

  2021cited by this paper
• Inhaled JAK inhibitor GDC-0214 reduces exhaled nitric oxide in patients with mild asthma: a randomized, controlled, proof-of-activity trial.

  2021cited by this paper
• Increased day‐to‐day fluctuations in exhaled breath profiles after a rhinovirus challenge in asthma

  2021cited by this paper
• Secreted heat shock proteins control airway remodeling: Evidence from bronchial thermoplasty.

  2021cited by this paper
• Long‐acting muscarinic antagonists and small airways in asthma: Which link?

  2021cited by this paper
• Asthma prescribing according to Arg16Gly beta-2 genotype: a randomised trial in adolescents

  2021cited by this paper
• Predicting response to benralizumab in chronic obstructive pulmonary disease: analyses of GALATHEA and TERRANOVA studies.

  2020cited by this paper
• Genome-wide association study of asthma exacerbations despite inhaled corticosteroid use

  2020cited by this paper
• Extracellular matrix remodelling in COPD

  2020cited by this paper
• Type 2 inflammation in eosinophilic chronic obstructive pulmonary disease

  2020cited by this paper
• Identification and treatment of T2-low asthma in the era of biologics

  2020cited by this paper
• β2-adrenoceptor modulation in COPD and its potential impact on cardiovascular comorbidities

  2020cited by this paper
• Inhibition of LTβR-signalling activates Wnt-induced regeneration in lung

  2020cited by this paper
• Why do some asthma patients respond poorly to glucocorticoid therapy?

  2020cited by this paper
• eNose breath prints as a surrogate biomarker for classifying patients with asthma by atopy

  2020cited by this paper
• eNose breathprints as a surrogate biomarker for classifying asthma patients by atopy.

  2020cited by this paper
• Wnt/β-catenin signaling is critical for regenerative potential of distal lung epithelial progenitor cells in homeostasis and emphysema

  2020cited by this paper
• The right treatment for the right patient with COPD: lessons from the IMPACT trial

  2020cited by this paper
• Airway Remodeling in Asthma

  2020cited by this paper
• Histopathological comparison of endobronchial biopsies from different pulmonary lobes of severe asthmatic patients.

  2020cited by this paper
• Sputum microbiome profiles identify severe asthma phenotypes of relative stability at 12-18 months.

  2020cited by this paper
• Omics for the future in asthma

  2020cited by this paper
• Beclomethasone dipropionate, formoterol fumarate and glycopyrronium bromide: Synergy of triple combination therapy on human airway smooth muscle ex vivo

  2020cited by this paper
• Serum levels of hyaluronic acid are associated with COPD severity and predict survival

  2019cited by this paper
• Effect of Indacaterol/Glycopyrronium on Pulmonary Perfusion and Ventilation in Hyperinflated Patients with Chronic Obstructive Pulmonary Disease (CLAIM). A Double‐Blind, Randomized, Crossover Trial

  2019cited by this paper
• Introduction to precision medicine in COPD

  2019cited by this paper
• A pilot study to test the feasibility of histological characterisation of asthma–COPD overlap

  2019cited by this paper
• CRP-guided antibiotic treatment in acute exacerbations of COPD in hospital admissions

  2019cited by this paper
• Endobronchial valves for severe emphysema

  2019cited by this paper
• Pharmacological strategies to regain steroid sensitivity in severe asthma and COPD.

  2019cited by this paper
• On Trapped Air and Trapped Blood in Chronic Obstructive Pulmonary Disease

  2019cited by this paper
• Eosinophil-guided corticosteroid therapy in patients admitted to hospital with COPD exacerbation (CORTICO-COP): a multicentre, randomised, controlled, open-label, non-inferiority trial.

  2019cited by this paper
• Long-term observational study on the impact of GLP-1R agonists on lung function in diabetic patients.

  2019cited by this paper
• Stability of the Blood Eosinophilic Phenotype in Stable and Exacerbated COPD.

  2019cited by this paper
• C-Reactive Protein Testing to Guide Antibiotic Prescribing for COPD Exacerbations.

  2019cited by this paper
• Bronchial thermoplasty decreases airway remodelling by blocking epithelium-derived heat shock protein-60 secretion and protein arginine methyltransferase-1 in fibroblasts

  2019cited by this paper
• Inhaled Janus Kinase (JAK) inhibitors for the treatment of asthma.

  2019cited by this paper
• Pharmacology and Therapeutics of Bronchodilators Revisited

  2019cited by this paper
• The pathogenicity of IL‐33 on steroid‐resistant eosinophilic inflammation via the activation of memory‐type ST2+CD4+ T cells

  2018cited by this paper
• Glucocorticoids and β2-agonists regulate the pathologic metabolism of hyaluronic acid in COPD.

  2018cited by this paper
• Collagen Degradation and Formation Are Elevated in Exacerbated COPD Compared With Stable Disease

  2018cited by this paper
• Efficacy and Safety of Dupilumab in Glucocorticoid‐Dependent Severe Asthma

  2018cited by this paper
• Triple therapy versus single and dual long-acting bronchodilator therapy in COPD: a systematic review and meta-analysis

  2018cited by this paper
• Possible involvement of acetylcholine-mediated inflammation in airway diseases.

  2018cited by this paper
• Once‐Daily Single‐Inhaler Triple versus Dual Therapy in Patients with COPD

  2018cited by this paper
• Clinical and inflammatory phenotyping by breathomics in chronic airway diseases irrespective of the diagnostic label

  2018cited by this paper
• Effect of procalcitonin-guided antibiotic treatment on mortality in acute respiratory infections: a patient level meta-analysis.

  2018cited by this paper
• Tiotropium formulations and safety: a network meta-analysis

  2017cited by this paper
• Mechanisms and treatments for severe, steroid‐resistant allergic airway disease and asthma

  2017cited by this paper
• β2-adrenergic receptors in inflammation and vascular complications of diabetes.

  2017cited by this paper
• Mesenchymal stem cells alleviate oxidative stress–induced mitochondrial dysfunction in the airways

  2017cited by this paper
• Oral Glucocorticoid–Sparing Effect of Benralizumab in Severe Asthma

  2017cited by this paper
• Targeting Mechanisms Linking COPD to Type 2 Diabetes Mellitus.

  2017cited by this paper
• Pharmacogenomics of inhaled corticosteroids and leukotriene modifiers: a systematic review

  2017cited by this paper
• Management of Chronic Obstructive Pulmonary Disease in Patients with Cardiovascular Diseases

  2017cited by this paper
• Intensified Therapy with Inhaled Corticosteroids and Long‐Acting &bgr;2‐Agonists at the Onset of Upper Respiratory Tract Infection to Prevent Chronic Obstructive Pulmonary Disease Exacerbations. A Multicenter, Randomized, Double‐Blind, Placebo‐controlled Trial

  2017cited by this paper
• Sputum or blood eosinophil association with clinical measures of COPD severity in the SPIROMICS cohort

  2017cited by this paper
• Tracheal Replacement Therapy with a Stem Cell‐Seeded Graft: Lessons from Compassionate Use Application of a GMP‐Compliant Tissue‐Engineered Medicine

  2017cited by this paper
• A phase I study for intravenous autologous mesenchymal stromal cell administration to patients with severe emphysema.

  2016cited by this paper
• Glucagon-Like Peptide 1 Receptor: A Novel Pharmacological Target for Treating Human Bronchial Hyperresponsiveness.

  2016cited by this paper
• Acute Exacerbations of COPD Are Associated With Increased Expression of Heparan Sulfate and Chondroitin Sulfate in BAL.

  2016cited by this paper
• A Randomized Trial of Long-Term Oxygen for COPD with Moderate Desaturation.

  2016cited by this paper
• Human Salivary Gland Stem Cells Functionally Restore Radiation Damaged Salivary Glands

  2016cited by this paper
• Bioengineering Lungs for Transplantation.

  2016cited by this paper
• Bronchoprotection and bronchorelaxation in asthma: New targets, and new ways to target the old ones.

  2016cited by this paper
• Metformin in severe exacerbations of chronic obstructive pulmonary disease: a randomised controlled trial

  2016cited by this paper
• Breathomics in lung disease.

  2015cited by this paper
• COPD Exacerbations Are Associated With Proinflammatory Degradation of Hyaluronic Acid.

  2015cited by this paper
• Acute exacerbations of COPD are associated with significant activation of matrix metalloproteinase 9 irrespectively of airway obstruction, emphysema and infection

  2015cited by this paper
• A new initiative on precision medicine.

  2015cited by this paper
• Effects of chronic treatment with the new ultra‐long‐acting β2‐adrenoceptor agonist indacaterol alone or in combination with the β1‐adrenoceptor blocker metoprolol on cardiac remodelling

  2015cited by this paper
• Selective inhibitors of the FK506-binding protein 51 by induced fit.

  2015cited by this paper
• Precision medicine--personalized, problematic, and promising.

  2015cited by this paper
• Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma.

  2014cited by this paper
• Asthma Therapy and Its Effect on Airway Remodelling

  2014cited by this paper
• Risk of Arrhythmias Associated with Ipratropium Bromide in Children, Adolescents, and Young Adults with Asthma: A Nested Case‐Control Study

  2014cited by this paper
• Airway gene expression in COPD is dynamic with inhaled corticosteroid treatment and reflects biological pathways associated with disease activity

  2013cited by this paper
• Bronchodilator responsiveness in patients with chronic heart failure.

  2013cited by this paper
• Corticosteroid resistance in patients with asthma and chronic obstructive pulmonary disease.

  2013cited by this paper
• Smooth muscle in tissue remodeling and hyper-reactivity: airways and arteries.

  2013cited by this paper
• Mechanisms of airway remodeling.

  2013cited by this paper
• Long-acting muscarinic receptor antagonists for the treatment of respiratory disease.

  2013cited by this paper

• Uncontrolled and severe asthma: predictive factors and comparison of control assessment tools

  2025cites this paper
• Potential of doxofylline in the treatment of chronic obstructive airway diseases (Review)

  2025cites this paper
• Performance-Enhancing Effects of Inhaled Medications: Implications for Heart, Muscle Function, and Doping Detection in Athletes

  2025cites this paper
• Disproportionate increase in COPD exacerbation risk for 3 months after discontinuing LAMA or ICS: insights from the FLAME trial

  2025cites this paper
• Euglena gracilis-derived β-glucan ameliorates particulate matter (PM2.5)-induced airway inflammation by modulating nuclear factor kappa B, mitogen-activated protein kinase, and nuclear factor erythroid 2-related factor 2 signaling pathways in A549 cells and BALB/c mice.

  2025cites this paper
• Animal models of chronic obstructive pulmonary disease and their role in drug discovery and development: a critical review

  2025cites this paper
• Effect of Cholinergic Receptor Antagonists on the Potentiation of the Effect of Adenosine Receptor Blockers in People with Bronchial Asthma

  2024cites this paper
• A clinician’s guide to single vs multiple inhaler therapy for COPD

  2024cites this paper
• Analysis of Key Genes and miRNA-mRNA Networks Associated with Glucocorticoids Treatment in Chronic Obstructive Pulmonary Disease

  2024cites this paper